developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeTagspancreatic cancer

#pancreatic cancer

All articles tagged with "pancreatic cancer"

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

Menta

Experimental pancreatic cancer pill shows major survival gain

Daraxonrasib was tested in 500 patients with metastatic pancreatic cancer.
Researchers reported average survival of 13.2 months versus 6.7 months on chemotherapy.
The daily pill was also described as causing fewer side effects than standard chemotherapy.

DE

DT Editorial Team·Jun 2, 2026·via newscientist.com

More in Science→

Revolution Medicines starts shipping experimental pancreatic cancer drug

Revolution Medicines Signals a New Phase for an Experimental Pancreatic Cancer Drug

Revolution Medicines says it has started shipping an experimental pancreatic cancer drug.
CEO Mark Goldsmith said an FDA submission is expected soon.
The update marks a shift from development narrative to regulatory preparation.
The available materials do not include the supporting clinical data or approval timeline.

DE

DT Editorial Team·May 30, 2026·via statnews.com

More in Health→

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

Pancreatic Cancer Study Suggests Lower CA19-9 Threshold Could Catch More High-Risk Patients

Researchers say some pancreatic cancer patients are misclassified by the standard CA19-9 cutoff.
About 10% of patients may not elevate CA19-9 because of genetic nonproducer status.
The study examined 615 patients using whole-exome sequencing for FUT2 and FUT3 genotypes.
A dual-threshold model could help identify high-risk disease hidden within the normal range.

DE

DT Editorial Team·May 21, 2026·via medicalxpress.com

More in Health→

Illustration of pancreatic cancer in a human body.

AI Study Suggests Pancreatic Cancer May Be Detectable Years Earlier on Routine CT Scans

Researchers used an AI model to analyze nearly 2,000 CT scans that had previously been cleared as normal.
The system reportedly identified subtle pancreatic irregularities linked to tissue that later became tumor.
The study suggests pancreatic cancer might be detectable up to three years earlier than standard clinical discovery.

DE

DT Editorial Team·May 7, 2026·via livescience.com

More in Science→

Tumor-on-a-chip study spotlights why pancreatic cancer is so hard to treat

A new tumor-on-a-chip model focuses on pancreatic cancer’s interaction with scar tissue
The work targets a core reason pancreatic tumors are difficult to treat
The platform could help researchers study treatment resistance in a more realistic setting

DE

DT Editorial Team·Apr 30, 2026·via medicalxpress.com

DE

DT Editorial Team·Apr 20, 2026·via statnews.com

DE

DT Editorial Team·Apr 19, 2026·via statnews.com

DE

DT Editorial Team·Apr 14, 2026·via nature.com

DE

DT Editorial Team·Apr 14, 2026·via medicalxpress.com

More in Health→

AACR 2026: More strong data for Revolution Medicines’ KRAS drug

Revolution Medicines highlights new KRAS pill data at AACR 2026

Revolution Medicines highlighted new AACR 2026 data for a KRAS-targeting pancreatic cancer pill.
The company framed the results as unusually strong, signaling confidence in the program.
The supplied source does not include detailed efficacy or safety figures, so the update remains an early signal rather than a final verdict.

More in Health→

The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades

A KRAS Drug Candidate Is Raising Hopes for Pancreatic Cancer Treatment

A Revolution Medicines drug candidate is being described as one of the most promising pancreatic cancer advances in decades.
The therapy targets KRAS, a long-frustrating protein in cancer drug development.
Available source material points to unusually strong early results but does not include full trial detail.

More in Health→

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature Medicine

Phase 2 Trial Suggests Elraglusib Extends Survival in Metastatic Pancreatic Cancer

Phase 2 trial compared elraglusib plus gemcitabine/nab-paclitaxel against chemotherapy alone in untreated metastatic pancreatic cancer.
Median overall survival was 10.1 months with elraglusib versus 7.2 months for chemotherapy alone.
One-year survival reached 44.1% in the combination arm compared with 22.3% in the control arm.

More in Health→

Experimental pancreatic cancer drug points to a rare survival gain in a hard-to-treat disease

The supplied source says pancreatic cancer remains among the deadliest and hardest cancers to treat.
A Northwestern-developed drug reportedly doubled one-year survival in a trial.
The available text is limited, so the result should be viewed as promising but still in need of fuller validation.

More in Health→